Market Overview:
The global lysosomal acid lipase deficiency (LALD) treatment market is expected to register a CAGR of 7.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of LALD, rising awareness about LALD and its treatment options, and technological advancements in the field of lysosomal acid lipase replacement therapy (LART). However, high cost associated with LART is likely to restrain the growth of this market during the forecast period. Based on type, the global lysosomal acid lipase deficiency (LALD) treatment market has been segmented into enzyme replacement therapy (ERT), kidney transplantation, and stem cell transplantation. ERT dominates this market owing to its high efficacy in treating patients with LALD. By application, Wolman disease accounts for majority share of this market followed by cholesterol ester storage disease (CESD). Geographically speaking North America dominates this market followed by Europe and Asia Pacific respectively.
 Treatment Industry Outlook.svg)
Product Definition:
Lysosomal acid lipase deficiency (LALD) is a rare inherited disorder that affects the ability to break down fats. People with LALD cannot properly digest fatty foods and may experience digestive problems, weight loss, and liver damage. There is no cure for LALD, but treatment can help manage symptoms. Treatment includes eating a diet low in fat and cholesterol, taking medications to help digestion, and sometimes receiving intravenous feeding (nutrition through a tube inserted into the stomach).
Enzyme Replacement Therapy:
Lysosomal acid lipase deficiency (LAL-D) is an autosomal recessive genetic disorder affecting the lysosomal enzyme system. This leads to accumulation of fat in multiple tissues including liver, bone marrow, spleen and peripheral nervous system. The disease may present with early-onset as a neonatalile form or adult-onset form with variable degrees of severity.
Kidney Transplantation:
Kidney transplantation is a surgical procedure to replace damaged or diseased kidney. Kidney transplantation is used in cases of end-stage renal disease (ESRD), when the patient has lost all ability to function and survive on his/her own, but can have a suitable donor. The major advantages of kidney transplant are that it provides patients with better quality of life, improves survival rate and reduces chronic complications such as diabetes & hypertension.
Application Insights:
The global market is segmented by application into cholesterol ester storage disease (CESD), Wolman disease, and other lysosomal acid lipase deficiency diseases. The CESD segment dominated the overall market in terms of revenue share in 2017. This is due to a high prevalence of the disorder coupled with availability of approved drugs for treatment such as Trusopt and Zetrapen which are used for the dietary management of this condition.
In addition, there has been an increase in research initiatives pertaining to new drug development for treating patients suffering from lysosomal acid lipase deficiency which is expected to boost growth over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of patients suffering from Lysosomal Acid Lipase deficiency, increasing awareness about LALD treatment options, and availability of well-developed healthcare facilities in this region. Moreover, high adoption rate for new technologies and rising healthcare expenditure are some other factors contributing to the growth of this regional market.
Asia Pacific is expected to grow at a lucrative CAGR during the forecast period owing to unmet needs regarding rare diseases such as LALD that affect huge population base globally and growing patient pool due to increased travel & tourism activities. Furthermore, government initiatives encouraging research collaborations between universities & research institutes and pharmaceutical companies will also boost drug development programs for rare disease treatments which will further drive growth over next eight years (from 2018 - 2030).
Growth Factors:
- Increasing prevalence of lysosomal acid lipase deficiency (LALD) is expected to drive the growth of the lysosomal acid lipase deficiency (LALD) treatment market.
- The increasing number of clinical trials for the development of novel therapies is also anticipated to propel the growth of this market in the near future.
- The growing awareness about lysosomal acid lipase deficiency (LALD) and its treatment options among people is likely to boost demand for these treatments in the coming years.
- Technological advancements in diagnosis and treatment procedures are projected to create new opportunities for players operating in this market over the forecast period.
- Growing investments by key players towards research and development activities are expected to fuel expansion of this market during forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Research Report
By Type
Enzyme Replacement Therapy, Kidney Transplantation, Stem Cell Transplantation
By Application
Wolman Disease, Cholesterol Ester Storage Disease (CESD)
By Companies
AstraZeneca plc, Merck & Co., Inc, Pfizer, Inc., Alexion Pharmaceutical Inc, Lonza Group Ltd., hermo Fisher Scientific, Teva Pharmaceutical Industries Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
237
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Report Segments:
The global Lysosomal Acid Lipase Deficiency (LALD) Treatment market is segmented on the basis of:
Types
Enzyme Replacement Therapy, Kidney Transplantation, Stem Cell Transplantation
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Wolman Disease, Cholesterol Ester Storage Disease (CESD)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca plc
- Merck & Co., Inc
- Pfizer, Inc.
- Alexion Pharmaceutical Inc
- Lonza Group Ltd.
- hermo Fisher Scientific
- Teva Pharmaceutical Industries Ltd.
 Treatment Market Overview.svg)
Highlights of The Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Enzyme Replacement Therapy
- Kidney Transplantation
- Stem Cell Transplantation
- By Application:
- Wolman Disease
- Cholesterol Ester Storage Disease (CESD)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lysosomal Acid Lipase Deficiency (LALD) Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Treatment Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
LALD is a rare inherited disorder that affects the ability to break down fats. This can lead to high levels of fat in the blood and other problems. Treatment typically includes medications and diet changes.
Some of the key players operating in the lysosomal acid lipase deficiency (lald) treatment market are AstraZeneca plc, Merck & Co., Inc, Pfizer, Inc., Alexion Pharmaceutical Inc, Lonza Group Ltd., hermo Fisher Scientific, Teva Pharmaceutical Industries Ltd..
The lysosomal acid lipase deficiency (lald) treatment market is expected to register a CAGR of 7.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Lysosomal Acid Lipase Deficiency (LALD) Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Lysosomal Acid Lipase Deficiency (LALD) Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Size & Forecast, 2018-2028
4.5.1 Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Size and Y-o-Y Growth
4.5.2 Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Absolute $ Opportunity
Chapter 5 Global Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Size Forecast by Type
5.2.1 Enzyme Replacement Therapy
5.2.2 Kidney Transplantation
5.2.3 Stem Cell Transplantation
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Size Forecast by Applications
6.2.1 Wolman Disease
6.2.2 Cholesterol Ester Storage Disease (CESD)
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Lysosomal Acid Lipase Deficiency (LALD) Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Size Forecast by Type
9.6.1 Enzyme Replacement Therapy
9.6.2 Kidney Transplantation
9.6.3 Stem Cell Transplantation
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Size Forecast by Applications
9.10.1 Wolman Disease
9.10.2 Cholesterol Ester Storage Disease (CESD)
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Lysosomal Acid Lipase Deficiency (LALD) Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Size Forecast by Type
10.6.1 Enzyme Replacement Therapy
10.6.2 Kidney Transplantation
10.6.3 Stem Cell Transplantation
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Size Forecast by Applications
10.10.1 Wolman Disease
10.10.2 Cholesterol Ester Storage Disease (CESD)
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Lysosomal Acid Lipase Deficiency (LALD) Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Size Forecast by Type
11.6.1 Enzyme Replacement Therapy
11.6.2 Kidney Transplantation
11.6.3 Stem Cell Transplantation
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Size Forecast by Applications
11.10.1 Wolman Disease
11.10.2 Cholesterol Ester Storage Disease (CESD)
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Lysosomal Acid Lipase Deficiency (LALD) Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Size Forecast by Type
12.6.1 Enzyme Replacement Therapy
12.6.2 Kidney Transplantation
12.6.3 Stem Cell Transplantation
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Size Forecast by Applications
12.10.1 Wolman Disease
12.10.2 Cholesterol Ester Storage Disease (CESD)
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Lysosomal Acid Lipase Deficiency (LALD) Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Size Forecast by Type
13.6.1 Enzyme Replacement Therapy
13.6.2 Kidney Transplantation
13.6.3 Stem Cell Transplantation
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Lysosomal Acid Lipase Deficiency (LALD) Treatment Market Size Forecast by Applications
13.10.1 Wolman Disease
13.10.2 Cholesterol Ester Storage Disease (CESD)
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Lysosomal Acid Lipase Deficiency (LALD) Treatment Market: Competitive Dashboard
14.2 Global Lysosomal Acid Lipase Deficiency (LALD) Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca plc
14.3.2 Merck & Co., Inc
14.3.3 Pfizer, Inc.
14.3.4 Alexion Pharmaceutical Inc
14.3.5 Lonza Group Ltd.
14.3.6 hermo Fisher Scientific
14.3.7 Teva Pharmaceutical Industries Ltd.
